Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823964 · ClinicalTrials.gov registry record · Phase 4
EASY: Extended Access to Sollpura Over Years
A Phase 4 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT02823964: Completed Phase 4 study, sponsored by Anthera Pharmaceuticals.
NCT02823964 is a Phase 4 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02823964, a Phase 4 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be formulated without enteric coating for administration either as a capsule or as a dosing solution dissolved in water or juice.
Primary Outcome
Descriptive analysis
Interventions
- DRUG Liprotamase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
What the finished NCT02823964 record still lists
NCT02823964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Liprotamase is the first listed.
NCT02823964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02823964 about?
NCT02823964 is a clinical study titled "EASY: Extended Access to Sollpura Over Years". Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be formulated without enteric coating for administration either as a capsule or as a dosing solution dissolved in water or juice.
What is the current status of trial NCT02823964?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2016-09. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02823964?
The interventions under investigation include: Liprotamase (DRUG).
Who is sponsoring clinical trial NCT02823964?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02823964's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia